Courtroom Wins Put Ball Back In Pfizer's Court For 2028+

Research evidence excerpt

Courtroom Wins Put Ball Back In Pfizer's Court For 2028+

Pharmaceuticals (Major) & Large Cap Biotechnology

Pharmaceuticals - Major - Market Weight

PFIZER (PFE) May 13, 2026

Courtroom Wins Put Ball Back In Pfizer's Court For 2028+ Rating:

Underperform

The Wolfe Byte Price: $25.87

A rather uneventful print for PFE. Shares closed +0.5% (DRG +0.6%) after a rev Price Target:

beat that likely warranted a guidance raise if it weren't for the unpredictable $26

COVID biz. New HSD 5-year sales CAGR ('28-'33) and Vyndamax exclusivity to Prior: $25

% Upside:

2031 nudge our PT up to $26 (from $25). 0.5%

View PFE Model

Ambitions of growing at HSD sales CAGR from '28-'33. New disclosure during the View Comp Table

call was Pfizer's (PFE) goal of achieving a 5-year revenue CAGR in the high-single Company Information

digits from '28-'33 (WR +2%, cons +1%), propelled by the company's newly launched 52-Week Range $22 - $29

& acquired products and further spurred by two key litigation wins (i.e., Vyndamax Market Cap. (MM) $147,445

Enterprise Value (MM) $199,944

patent settlement with exclusivity until June 1, 2031 & Belgian court defending its Shares Out. (MM) 5,699.4

EU contracts). Avg. Value Traded (MM) $1,126.59

Adj. Debt to Cap 44.7%

A new 35-serotype adult PCV revealed. PFE unveiled a 35-serotype PCV for adults SI% of Float 2.5%

slated to enter development later this year. While the concept is intriguing to us, FCF Yield (24.8)% EV/ EBITDA 12.0x

questions remain on the underlying technology supporting such broad coverage Target Multiple NA

without sacrificing individual serotype efficacy. Additionally for pediatrics, the phase Dividend Yield 6.7%

3 trial for the 25-valent PCV kicked off last week. After adding these next-gen assets Price Performance